Prescription drug · NDA
Apriso (mesalamine) NDC 65649-103
Mesalamine 375 mg/1 · Capsule, Extended release · Oral · Salix Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 65649-103-01 | 65649010301 | 1 BOTTLE in 1 CARTON (65649-103-01) / 4 CAPSULE, EXTENDED RELEASE in 1 BOTTLEMarketed from Oct 31, 2008 · Sample package | |
| 65649-103-02 | 65649010302 | 1 BOTTLE in 1 CARTON (65649-103-02) / 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLEMarketed from Oct 31, 2008 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Apriso
- Generic name (nonproprietary)
- mesalamine
- Active ingredients
- Mesalamine — 375 mg/1
- Dosage form
- Capsule, Extended release
- Route
- Oral
- Labeler
- Salix Pharmaceuticals, Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 022301
- Marketing start
- Listing expires
- Other FDA classes
- Aminosalicylic Acids (Chemical structure)
- Identifiers
- Product ID 65649-103_5a0ee848-80a0-294e-e063-6394a90a08aaSPL ID 5a0ee848-80a0-294e-e063-6394a90a08aaSPL set ID 7951139c-b271-45a4-b523-34b23800917bRxCUI 825130, 825134UNII 4Q81I59GXC
- Pharmacologic class
- Aminosalicylate
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N465649010301followed by a unit qualifier and the quantityPackage 65649-0103-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
APRISO ® is indicated for the maintenance of remission of ulcerative colitis in adults. APRISO is an aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adults. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 022301
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| mesalamine | Mesalamine 375 mg/1 | Capsule, Extended releaseOral | Oceanside Pharmaceuticals | 68682-113 |
| mesalamine | Mesalamine 375 mg/1 | Capsule, Extended releaseOral | Teva Pharmaceuticals USA, Inc. | 0093-9224 |